ProMIS Neurosciences (NASDAQ:PMN) Stock Price Up 4% – Here’s What Happened

ProMIS Neurosciences, Inc. (NASDAQ:PMN)’s share price was up 4% during trading on Tuesday . The stock traded as high as $1.06 and last traded at $1.04. Approximately 39,830 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 70,514 shares. The stock had previously closed at $1.00.

ProMIS Neurosciences Stock Up 4.0 %

The business has a 50 day moving average price of $1.24 and a two-hundred day moving average price of $1.64. The stock has a market cap of $19.72 million, a P/E ratio of -1.41 and a beta of 0.61.

ProMIS Neurosciences (NASDAQ:PMN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. On average, research analysts forecast that ProMIS Neurosciences, Inc. will post -0.24 earnings per share for the current year.

Insider Transactions at ProMIS Neurosciences

In related news, Director Madge K. Shafmaster acquired 70,000 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average price of $1.28 per share, with a total value of $89,600.00. Following the acquisition, the director now directly owns 138,333 shares of the company’s stock, valued at approximately $177,066.24. This trade represents a 100.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In other news, Director Madge K. Shafmaster bought 60,000 shares of the stock in a transaction dated Friday, September 20th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $75,000.00. Following the transaction, the director now owns 68,333 shares of the company’s stock, valued at $85,416.25. The trade was a 700.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Madge K. Shafmaster purchased 70,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average cost of $1.28 per share, for a total transaction of $89,600.00. Following the purchase, the director now owns 138,333 shares of the company’s stock, valued at $177,066.24. This represents a 100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 140,000 shares of company stock valued at $177,100. 6.39% of the stock is currently owned by corporate insiders.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.